ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 12.8 | 10.8 | 11.4 |
| Other income | 0.1 | 0.1 | 0.0 |
| Total income | 12.9 | 11.0 | 11.4 |
| Profit before exceptional items & tax | 1.1 | 0.2 | 1.3 |
| Exceptional items | 0.0 | 0.8 | 0.0 |
| Profit before tax | 1.1 | 0.9 | 1.3 |
| Net profit | 1.0 | 0.3 | 0.9 |
| Operating margin | 8.5% | 8.2% | 11.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +11.10% |
|---|---|
| Net profit, quarter on quarter | +233.30% |
| Revenue, year on year | +12.30% |
BSE results filing, NSE: CHOKSILA. Figures extracted from the filing.
Choksi Laboratories Ltd: key numbers
- Share price
- ₹199.65
- Market cap
- ₹139.1 Cr
- Revenue (annual)
- ₹46.01 Cr
- Net profit (annual)
- ₹1.96 Cr
- P/E (TTM)
- 64.3×Sector 54.5×
- Promoter holding
- 31.48%+0.00% QoQ
- FII holding
- 10.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Choksi Laboratories Ltd
All →Choksi Laboratories Board Meeting Date
Choksi Laboratories schedules a 14 November 2026 board meeting to consider unaudited standalone half-yearly results for September 2026. Trading window closes from 1 October until 16 November 2026.
Choksi Laboratories Business Update
Choksi Laboratories received the USFDA Establishment Inspection Report for its Indore central laboratory, closing the August 2026 inspection. No monetary penalty or fine is mentioned.
Choksi Laboratories Convertible Warrants
Choksi Laboratories' proposed convertible warrants issue was rejected at its EGM on October 17, 2026. The company requests BSE to close the in-principle approval application.
Choksi Laboratories Convertible Warrants
Choksi Laboratories' EGM on 17 Oct 2026 rejected the special resolution to allot convertible warrants to promoters. 99.46% of votes polled were against, blocking the capital raise.
Choksi Laboratories Convertible Warrants
Choksi Laboratories held an EGM regarding the issuance of convertible warrants on a preferential basis. The promoters and proposed allottees abstained from voting on the resolution.
Choksi Laboratories Other Announcement
Choksi Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.